203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I

T follicular helper cells are mis localized in idiopathic multicentric castleman disease

Rituximab for KSHV associated multicentric castleman disease A phase II safety efficacy trial

Xgboost profiling of quantitative lymph node and symptom signatures distinguishes idiopathic multicentric castleman disease and its clinical subtypes

Castleman disease as a spectrum Characterization of novel subtypes using data from the spanish GELTAMO registry

Extrafollicular B cell expansion in COVID 19 patients with prothrombotic antibodies linked to inflammatory and Th1 signatures

Idiopathic multicentric castleman disease tafro A potentially curable disease

Prognostic significance of pulmonary involvement in idiopathic multicentric castleman disease

Idiopathic multicentric castleman disease unresponsive to one IL 6 inhibitor may respond to another IL 6 inhibitor

Humanized anti CD25 monoclonal antibody for previously treated hemophagocytic lymphohistiocytosis in adults A prospective open label clinical trial

Senescence prone immune cell subsets expand in the aged environment

Memory NKG2C NK cells develop from NKG2C transitional precursors and persist within secondary lymphoid organs